RxDoctor Payments DataLook up a doctor →

Mark Rivellese, MD

Ophthalmology · Atlanta, GANPI 1891798039

Payments from drug & device makers

$39,930in general payments, 2019–2025

Across 205 payments — averaging $194.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$29K
  • Alcon$4K
  • Genentech USA, Inc.$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • AbbVie$798
  • Apellis Pharmaceuticals, Inc.$484
  • plus $3K from 12 others

What the payments were for

  • Travel & lodging$3851%
  • Food & beverage$10,16726%
  • Ownership interest$28,86873%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,930 in reported general payments places this provider in the 90th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$3,065,950
Medicare patients
931
Services billed
48,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bromfenac Sodium68$13,252
ProlensaBromfenac Sodium25$8,642
Prednisolone Acetate139$7,129
CombiganBrimonidine Tartrate/Timolol16$5,913
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol16$2,674
Ketorolac Tromethamine102$2,644
Difluprednate15$1,417
Atropine Sulfate19$929
Timolol Maleate69$658
MoxifloxacinMoxifloxacin Hcl38$648
Latanoprost48$443
Dorzolamide Hcl17$369
Brimonidine Tartrate25$323
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat16$309
Ciprofloxacin Hcl19$283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$18$8,64225 claims
AbbVieCombigan$798$5,91316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →